The increasing awareness related to the treatment of hypertension-related disease further contributes to the pulmonary arterial hypertension market. There has been a rise in hypertension disease and mental health awareness initiatives across the globe. The need for these awareness programs is necessary as well due to the increasing level of hypertension disorders due to high stress in individuals. There are various organizations and educational institutions such as ALAS Pro Salud Mental and Stanford University that have taken immense steps to spread awareness programs. These programs are assisting individuals to notice behavior change and other hypertension and stress-related symptoms in their daily lives on accounts of which the demand for stress management services and products is increasing.
To learn more about this report request a free sample copy at https://www.omrglobal.com/request-sample/pulmonary-arterial-hypertension-market
Moreover, alcohol consumption and unhealthy habits further encourage the risk of pulmonary arterial hypertension that further propels the market growth. Additionally, the rising youth population around the globe will further give rise to the excessive consumption of alcohol; increased alcohol consumption will further give rise to heart diseases. According to the World Youth Report (2018), there were around 1.2 billion young people aged between 15 to 24 years, accounting for 16.0% of the global population, that consumes alcohol. As per the United Nations (UN), by 2030, the number of the youth population is anticipated to have grown by 7.0%, to nearly 1.3 billion. As per the Population Reference Bureau (PRB), the global population ages 15-24 and 25-64 were 65% in 2018. The people aged 15 to 40 years tend to consume alcohol and thereby drive the growth of the market.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/pulmonary-arterial-hypertension-market
Emerging economies likely to account significant contribution in the pulmonary arterial hypertension market
Globally, the Asia-Pacific region is considered to be the most emerging market due to the significant growth of the healthcare system in Asia-Pacific countries such as India, Japan, China, Korea and so on. Asia-Pacific region is expected to witness immense growth and development in the healthcare sector due to significant investment, favorable government policies, rising pulmonary arterial hypertension, and other heart diseases. Asia includes more than 60% of the world’s population. India and China hold more than half of the total population of Asia.Asia-Pacific region is becoming a medical hub and a variety of patients from across the globe travels miles to get quality treatment at economic prices in the Asia-Pacific region.
Further, the rising investment and initiatives from the government of various emerging economies of Asia-Pacific such as China, India, Singapore, South Korea along with many other economies towards the adoption of a healthy lifestyle tend to accelerate the market share of stress management in the region. For instance, in May 2018, the Government of India launched one of the most progressive initiatives named Ayushman Bharat Yojana, the country’s biggest healthcare initiative to date. It is one of the largest healthcare schemes in India; it will provide $7,000 health cover to 50 crore impoverished families in the country for various diseases including pulmonary arterial hypertension disorders as well.
Global Pulmonary arterial hypertension Market Segmentation
By Drug Type
- Endothelin Receptor Antagonists (ERA)
- Calcium Channel Blockers
- Prostacyclin and Prostacyclin Analogs
- Phosphodiesterase 5 (PDE-5)
- Others (Soluble Guanylate Cyclase (SGC) Stimulators)
Global Pulmonary arterial hypertension Market – Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
Company Profiles
- AOP Orphan Pharmaceuticals AG
- Arena Pharmaceuticals, Inc.
- Bayer AG
- Bristol Myers Squibb Co.
- Eli Lilly and Co.
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Johnson & Johnson Services, Inc.
- Novartis International AG
- Pfizer Inc.
- Phase Bio Pharmaceuticals, Inc.
- Proteo Biotech AG
- Teva Pharmaceutical Industries Ltd.
- United Therapeutics Corp.
- VIVUS Inc.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
